Reportlinker Adds Cell Therapy - Technologies, Markets and Companies
NEW YORK, Nov. 9, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Cell Therapy - Technologies, Markets and Companies
http://www.reportlinker.com/p0203537/Cell-Therapy---Technologies-Markets-and-Companies.html
Summary
This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.
Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.
Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.
Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.
Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.
The cell-based markets was analyzed for 2009, and projected to 2019. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.
The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 268 of these are profiled in part II of the report along with tabulation of 252 alliances. Of these companies, 150 are involved in stem cells. Profiles of 68 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 49 Tables and 11 Figures. The bibliography contains 1,000 selected references, which are cited in the text.
TABLE OF CONTENTS
0. Executive Summary 21
1. Introduction to Cell Therapy .. 25
Introduction . 25
Historical landmarks of cell therapy . 25
Interrelationship of cell therapy technologies . 27
Cells and organ transplantation .. 27
Cells and protein/gene therapy .. 28
Cell therapy and regenerative medicine .. 29
Cells therapy and tissue engineering 29
Therapy based on cells involved in disease 30
Advantages of therapeutic use of cells 30
Use of cells for improving drug delivery.. 31
2. Cell Therapy Technologies .. 33
Introduction . 33
Cell types used for therapy 33
Sources of cells 33
Xenografts . 34
Cell lines . 34
Immortalized cells . 34
Blood component therapy . 34
Therapeutic apheresis .. 34
Leukoreduction .. 35
Platelet therapy . 35
Basic technologies for cell therapy 36
Cell culture 36
Observation of stem cell growth and viability 36
Companies involved in cell culture 37
Cell sorting 38
Flow cytometry .. 38
A dielectrophoretic system for cell separation .. 39
Molecular beacons for specific detection and isolation of stem cells .. 39
Multitarget magnetic activated cell sorter .. 40
Nanocytometry .. 40
Companies supplying cell sorters . 40
Dynabead technology for cell sorting .. 41
ALDESORTER system for isolation of stem cells 41
Adult stem cell sorting by identification of surface markers . 42
Cell analysis .. 42
Preservation of cells 43
Innovations in cryopreservation 43
Packaging of cells 43
Selective expansion of T cells for immunotherapy . 44
Cloning and cell therapy 44
Techniques for cell manipulation . 45
Cell-based drug discovery .. 45
Cells as vehicles for drug delivery .. 48
RBCs as drug delivery vehicles 48
Drug delivery systems for cell therapy 48
Intravenous delivery of stem cells .. 48
Pharmacologically active microcarriers .. 49
Devices for delivery of cell therapy . 49
Artificial cells 50
Applications of artificial cells . 50
Cell encapsulation .. 51
Diffusion capsule for cells .. 51
Encapsulated cell biodelivery 52
Therapeutic applications of encapsulated cells 52
Nitric oxide delivery by encapsulated cells 53
Implantation of microencapulated genetically modified cells .. 54
Ferrofluid microcapsules for tracking with MRI 54
Companies involved in encapsulated cell technology . 55
Electroporation 55
Gene therapy 56
Cell-mediated gene therapy . 56
Fibroblasts .. 56 - 4 -
Chondrocyte 57
Skeletal muscle cells 57
Vascular smooth muscle cells 58
Keratinocytes . 58
Hepatocytes 59
Lymphocytes .. 59
Mammalian artificial chromosomes .. 59
In vivo tracking of cells .. 59
Molecular imaging for tracking cells 60
MRI technologies for tracking cells .. 60
Superparamagnetic iron oxide nanoparticles as MRI contrast agents 61
Visualization of gene expression in vivo by MRI .. 61
Role of nanobiotechnology in development of cell therapy 61
Cell transplantation for development of organs .. 62
Cells transplantation and tolerance .. 62
Strategies to improve tolerance of transplanted cells 63
Encapsulation to prevent immune rejection .. 63
Prevention of rejection of xenotransplants . 63
Expansion of allospecific regulatory T cells 64
Removal and replacement of pathogenic cells of the body . 64
Therapeutic leukocytapheresis . 64
3. Stem Cells 65
Introduction . 65
Biology of stem cells . 66
Embryonic stem cells .. 66
Growth and differentiation of ESCs . 66
Mechanisms of differentiation of ESCs .. 67
Chemical regulation of stem cell differentiation 67
In vitro differentiation of hESCs 67
SIRT1 regulation during stem cell differentiation . 67
Regulation of stem cell self-renewal and differentiation 68
hESCs for reprogramming human somatic nuclei 68
Stem cells differentiation in the pituitary gland 68
Influence of microenvironment on ESCs 69
Role of genes in differentiation of ESCs . 69
Global transcription in pluripotent ESCs . 69
Role of p53 tumor suppressor gene in stem cell differentiation .. 70
Role of Pax3 gene in stem cell differentiation 70
Signaling pathways and ESC genes . 70
Epigenetics of hESCs .. 71
Chromatin as gene regulator for ESC development . 71
Comparison of development of human and mouse ESCs . 72
Mechanism of regulation of stem cells for regeneration of body tissues .. 72
Role of microenvironments in the regulation of stem cells 73
Regulation and regeneration of intestinal stem cells .. 73
Parthenogenesis and human stem cells . 73
Uniparental ESCs .. 74
Bone marrow stem cells . 75
Hematopoietic stem cells 75
Role of HSCs in the immune system 77
Derivation of HSCs from ESCs .. 77
Mesenchymal stem cells.. 77
Multipotent adult progenitor cells . 79
Side population (SP) stem cells . 79
Differentiation of adult stem cells 79
Growth and differentiation of HSCs 81
Signaling pathways in the growth and differentiation of HSCs . 81
Mathematical modeling of differentiation of HSCs 81
Role of prions in self renewal of HSCs . 82
Sources of stem cells 82
Sources of human embryonic stem cells .. 82
Nuclear transfer to obtain hESCs. 82
Direct derivation of hESCs from embryos without nuclear transfer .. 83
Alternative methods of obtaining hESCs 84
Establishing hESC lines without destruction of embryo .. 84
Altered nuclear transfer .. 85
Small embryonic-like stem cells 85
Advantages and disadvantages of ESCs for transplantation 85
Use of ESC cultures as an alternative source of tissue for transplantation . 86
Spermatogonial stem cells 87 - 5 -
Amniotic fluid as a source of stem cells . 88
Generation of iPS cells from AF cells 88
Placenta as source of stem cells .. 89
Amnion-derived multipotent progenitor cells. 89
Placenta as a source of HSCs . 89
Umbilical cord as a source of MSCs . 90
Umbilical cord blood as source of neonatal stem cells .. 90
Cryopreservation of UCB stem cells . 91
UCB as source of MSCs 91
Applications of UCB .. 91
Advantages of UCB .. 92
Limitations of the use of UCB. 92
Licensing and patent disputes involving UCB 94
Infections following UCB transplants 94
Unanswered questions about UCB transplantation .. 94
Companies involved in UCB banking 95
UCB banking in the UK 96
US national UCB banking system . 97
Future prospects of UCB as a source of stem cells .. 97
Induced pluripotent stem cells derived from human somatic cells 98
Characteristics of iPSCs . 98
DNA methylation patterns of iPS cells 99
iPSCs derived from skin . 99
iPSCs derived from blood .. 99
Use of retroviral vectors for generation of iPSCs . 100
Use of non-integrating viral vectors for generation of iPSCs . 101
Clinical relevance of iPSCs .. 101
Sources of adult human stem cells . 102
Adipose tissue as a source of stem cells . 103
Transforming adult adipose stem cells into other cells 103
Regulation of adipose stem cells differentiation . 104
iPSCs derived from adult human adipose stem cells 104
Skin as a source of stem cells 104
Controlling the maturation of embryonic skin stem cells . 104
Epidermal neural crest stem cells .. 105
Follicle stem cells 105
Mesenchymal stem cells in skin . 106
Regulation of stem cells in hair follicles 106
Skin-derived precursor cells 106
Stem cells in teeth 107
Peripheral blood stem cells . 107
Spleen as a source of adult stem cells 108
Search for master stem cells . 108
Vascular cell platform to self-renew adult HSC . 108
Adult stem cells vs embryonic stem cells . 109
Biological differences between adult and embryonic stem cells .. 109
Neural crest stem cells from adult hair follicles 109
Transdifferentiation potential of adult stem cells . 110
Limitations of adult stem cells .. 111
Comparison of human stem cells according to derivation 111
VENT cells 112
Stem cell banking 112
Stem cell technologies .. 113
Analysis of stem cell growth and differentiation .. 113
Tracking self-renewal and expansion of transplanted muscle stem cells .. 113
Stem cell biomarkers 113
Endoglin as a functional biomarker of HSCs 114
STEMPRO? EZChek? for analysis of biomarkers of hESCs . 114
SSEA-4 as biomarker of MSCs 114
p75NTR as a biomarker to isolate adipose tissue-derived stem cells .. 114
Neural stem cell biomarker . 115
Protein expression profile as biomarker of stem cells .. 115
Real-time PCR for quantification of protein biomarkers .. 115
Study of stem cell pathways .. 116
Study of stem cell genes . 116
Gene inactivation to study hESCs . 116
RNAi to study gene inactivation in hESCs 117
Study of ESC development by inducible RNAi. 117
Targeting Induced Local Lesions in Genomes . 118
Homologous recombination of ESCs.. 118
Immortalization of hESCs by telomerase . 118 - 6 -
Gene modification in genomes of hESCs and hiPSCs using zinc-finger nuclease . 119
miRNA and stem cells .. 119
Role of miRNAs in gene regulation during stem cell differentiation .. 119
Influence of miRNA on stem cell formation and maintenance 120
Transcriptional regulators of ESCs control miRNA gene expression . 120
Stem cells and cloning . 121
Cell nuclear replacement and cloning 121
Nuclear transfer and ESCs 121
Cloning from differentiated cells . 122
Cloning mice from adult stem cells 123
Creating interspecies stem cells . 123
Cloned cells for transplantation medicine 124
Claims of cloning of hESCs .. 124
Cytogenetics of embryonic stem cells . 125
Engraftment, mobilization and expansion of stem cells . 126
Adipogenesis induced by adipose tissue-derived stem cells 127
Antisense approach for preservation and expansion of stem cells 127
Biomatrials for ESC growth.. 128
Chemoattraction of neuronal stem cells through GABA receptor .. 128
Enhancement of HSC engraftment by calcium-sensing receptor .. 128
Enhancement of stem cell differentiation by Homspera .. 129
Ex vivo expansion of human HSCs in culture . 129
Ex vivo expansion of MSCs .. 130
Expansion of HSCs in culture by inhibiting aldehyde dehydrogenase .. 130
Expansion of adult stem cells by activation of Oct4 . 130
Expansion of transduced HSCs in vivo . 131
Mobilization of HSCs by growth factors 131
Mobilization of stem cells by cytokines/chemokines . 132
Mobilization of adult human HSCs by use of inhibitors 132
Mobilization of stem cells by HYC750 133
Mobilization of stem cells by hyperbaric oxygen 133
Mobilization by adenoviral vectors expressing angiogenic factors 134
Selective mobilization of progenitor cells from bone marrow . 134
Selective Amplification .. 134
Stem cell mobilization by acetylcholine receptor agonists .. 135
Use of parathyroid hormone to increase HSC mobilzation .. 135
Expansion of stem cells in vivo by Notch receptor ligands . 135
Technologies for inducing differentiation of stem cells 135
Use of lineage selection to induce differentiation of hESCs. 135
Growth factor-induced differentiation of MAPCs . 136
Neurotrophin-mediated survival and differentiation of hESCs 136
Generation of RBCs from hematopoietic stem cells .. 136
Generation of multiple types of WBCs from hESCs and iPSCs 137
Use of RNAi to expand the plasticity of autologous adult stem cells 137
Use of carbohydrate molecules to induce differentiation of stem cells 137
Mechanical strain to induce MSC differentiation . 138
Limitations of the currently available stem cell lines in the US 138
Contaminating material in stem cell culture and measures to eliminate it 138
Stem cell separation . 140
Stem cell culture 140
Conversion of stem cells to functioning adipocytes . 141
Mass production of ESCs . 141
Promoting survival of dissociated hESCs 142
Analysis and characterization of stem cells 142
Havesting and identification of EPCs 142
Labeling of stem cells .. 143
Quantum dots for labeling stem cells 143
Imaging and tracking of stem cells in vivo. 143
Quantum dot imaging for ESCs .. 143
Perfluorocarbon nanoparticles to track therapeutic cells in vivo 144
Project for imaging in stem cell therapy research . 144
Applications of stem cells 144
Commercial development and applications of adult stem cells 145
Retrodifferentiation of stem cells 145
MultiStem . 145
Controlling the maintenance process of hematopoietic stem cells .. 146
Self renewal and proliferation of HSCs . 146
Aging and rejuvenation of HSCs . 146
Peripheral blood stem cell transplantation . 146
Stem cell transplantation for radiation sickness .. 147
Stem cells and human reproduction 147 - 7 -
Expansion of spermatogonial stem cells .. 147
Conversion of ESCs into spermatogonial stem cells . 147
Conversion of stem cells to oocytes .. 148
ESCs for treatment of infertility in women .. 148
Cloning human embryos from oocytes matured in the laboratory 149
In utero stem cell transplantation . 149
Innovations in delivery of stem cells 150
Immunological aspects of hESC transplantation .. 150
Immunosuppression to prevent rejection of hESC transplants .. 151
Histocompatibility of hESCs . 151
Strategies for promoting immune tolerance of hESCs . 151
Stem cells for organ vascularization 152
Activation of EphB4 to enhance angiogenesis by EPCs 153
Advantages and limitations of clinical applications of MSCs .. 153
Biofusion by genetically engineering stem cells 153
Stem cell gene therapy 154
Combination of gene therapy with nuclear transfer .. 154
Gene delivery to stem cells by artificial chromosome expression . 154
Genetic manipulation of ESCs . 155
Genetic engineering of human stem cells for enhancing angiogenesis 155
HSCs for gene therapy .. 155
Helper-dependent adenoviral vectors for gene transfer in ESCs .. 156
Lentiviral vectors for in vivo gene transfer to stem cells . 156
Linker based sperm-mediated gene transfer technology . 157
Mesenchymal stem cells for gene therapy .. 157
Microporation for transfection of MSCs . 157
Regulation of gene expression for SC-based gene therapy 157
Stem cells and in utero gene therapy .. 158
Therapeutic applications for hematopoietic stem cell gene transfer . 158
The future of hematopoietic stem cell gene therapy 158
Stem cell pharmaceutics . 159
Cardiomyocytes derived from hESCs 159
Engineered stem cells for drug delivery to the brain 160
ESCs as source of models for drug discovery . 160
Hepatocytes derived from hESCs .. 161
Pharmaceutical manipulation of stem cells . 161
Role of stem cells in therapeutic effects of drugs .. 163
Stem cells for drug discovery . 163
Stem cell activation for regeneration by using glucocortoids . 164
Toxicology and drug safety studies using ESCs . 165
Future challenges for stem cell technologies . 167
Study of the molecular mechanism of cell differentiation .. 167
MBD3-deficient ESC line . 168
In vivo study of human hemopoietic stem cells 168
Stem cell biology and cancer . 168
Research into plasticity of stem cells from adults 169
Stem cells and aging 169
Activation of bone marrow stem cells into therapeutic cells . 170
Role of nitric oxide in stem cell mobilization and differentiation .. 170
Stem cell genes . 171
Gene expression in hESCs 171
The casanova gene in zebrafish . 172
Nanog gene .. 172
Stem cell proteomics 173
hESC phosphoproteome 174
Proteomic studies of mesenchymal stem cells 174
Proteomic profiling of neural stem cells 174
Proteome Biology of Stem Cells Initiative 175
Genomic alterations in cultured hESCs 175
Hybrid embryos/cybrids for stem cell research . 175
Generation of patient-specific pluripotent stem cells .. 176
Markers for characterizing hESC lines . 177
Switch of stem-cell function from activators to repressors 177
Stem cell research at academic centers 178
International Regulome Consortium 179
Companies involved in stem cell technologies .. 179
Concluding remarks about stem cells 184
Challenges and future prospects of stem cell research . 184
4. Clinical Applications of Cell Therapy 187
Introduction .. 187 - 8 -
Cell therapy for hematological disorders . 187
Transplantation of autologous hematopoietic stem cells 187
Hemophilias 187
Ex vivo cell/gene therapy of hemophilia B .. 187
Cell/gene therapy of hemophilia A . 188
Hematopoietic stem cell therapy for thrombocytopenia . 189
Stem cell transplant for sickle cell anemia . 189
Treatment of chronic acquired anemias.. 190
Implantation of genetically engineered HSCs to deliver rhEpo .. 190
Drugs acting on stem cells for treatment of anemia . 190
Stem cell therapy of hemoglobinopathies .. 191
Stem cells for treatment of immunoglobulin-light chain amyloidosis . 191
Future prospects of cell therapy of hematological disorders . 191
Cell therapy for immunological disorders 192
Role of dendritic cells in the immune system 192
Modifying immune responses of DCs by vaccination with lipiodol-siRNA mixtures . 192
Stem cell therapy of chronic granulomatous disease .. 193
Stem cell therapy of X-linked severe combined immunodeficiency . 193
Stem cell therapy of autoimmune disorders .. 194
Treatment of Crohn's disease with stem cells 194
Treatment of rheumatoid arthritis with stem cells 194
Stem cell transplants for scleroderma .. 195
Role of T-Cells in immunological disorders . 195
Autologous T-cells from adult stem cells . 196
Cell therapy for graft vs host disease .. 196
Cell therapy for viral infections . 197
T-cell therapy for CMV .. 197
T-cell therapy for HIV infection .. 198
T-cell immunity by Overlapping Peptide-pulsed Autologous Cells . 198
Anti-HIV ribozyme delivered in hematopoietic progenitor cells . 199
Dendritic-cell targeted DNA vaccine for HIV 199
Cell therapy of lysosomal storage diseases . 199
Niemann-Pick disease .. 200
Gaucher's disease . 200
Fabry's disease .. 201
Cell therapy for diabetes mellitus 201
Limitations of current treatment .. 202
Limitations of insulin therapy for diabetes mellitus .. 202
Limitations of pancreatic transplantation . 202
Islet cell transplantation . 203
Autologous pancreatic islet cell transplantation in chronic pancreatitis .. 203
Clinical trials of pancreatic islet cell transplants for diabetes . 203
Drawbacks of islet cell therapy .. 204
Use of an antioxidant peptide to improve islet cell transplantation .. 204
Cdk-6 and cyclin D1 enhance human beta cell replication and function . 205
A device for delivery of therapeutic cells in diabetes 205
Monitoring of islet cell transplants with MRI 205
Concluding remarks about allogeneic islet transplantation for diabetes . 206
Encapsulation of insulin producing cells . 206
Encapsulated porcine pancreatic islet cells for pancreas . 206
Encapsulated insulinoma cells . 207
Magnetocapsule enables imaging/tracking of islet cell transplants .. 207
Islet precursor cells .. 208
Dedifferentiation of ? cells to promote regeneration .. 208
Xenotransplantation of embryonic pancreatic tissue .. 209
Non-pancreatic tissues for generation of insulin-producing cells . 209
Exploiting maternal microchimerism to treat diabetes in the child . 209
Bio-artificial substitutes for pancreas .. 210
Role of stem cells in the treatment of diabetes 210
Embryonic stem cells for diabetes . 210
HSC transplantation to supplement immunosuppressant therapy 211
Human neural progenitor cells converted into insulin-producing cells . 212
Insulin-producing cells derived from UCB stem cells 212
iPS cells for diabetes . 213
Isolation of islet progenitor cells 213
Pancreatic progenitor cells Expansion in vitro 213
Pancreatic stem cells . 213
Stem cell injection into portal vein of diabetic patients 214
Dendritic cell-based therapy for type 1 diabetes.. 214
Gene therapy in diabetes 215
Viral vectors for gene therapy of diabetes .. 215 - 9 -
Genetically engineered dendritic cells .. 215
Genetically altered liver cells .. 216
Genetically modified stem cells .. 216
Companies developing cell therapy for diabetes .. 216
Concluding remarks about cell and gene therapy of diabetes .. 217
Cell therapy of gastrointestinal disorders 218
Inflammatory bowel disease .. 218
Cell therapy for liver disorders . 219
Types of cells and methods of delivery for hepatic disorders 219
Bioartificial liver . 220
Limitations of bioartificial liver 221
Stem cells for hepatic disorders 221
Deriving hepatocytes from commercially available hMSCs . 222
Implantation of hepatic cells derived from hMSCs of adipose tissue 222
MSC derived molecules for reversing hepatic failure 222
Cell-based gene therapy for liver disorders 223
Transplantation of genetically modified fibroblasts 223
Transplantation of genetically modified hepatocytes 223
Intraperitoneal hepatocyte transplantation . 224
Genetically modified hematopoietic stem cells .. 224
Use of iPSCs derived from somatic cells for liver regeneration . 224
Clinical applications .. 224
Future prospects of cell-based therapy of hepatic disorders . 225
Cell therapy of renal disorders .. 225
Bioartificial kidney . 226
Cell-based repair for vascular access failure in renal disease .. 226
Mesangial cell therapy for glomerular disease .. 226
Stem cells for renal disease 227
Role of stem cells in renal repair 227
Bone marrow stem cells for renal disease .. 227
MSC therapy for renal disease 228
Cell therapy for pulmonary disorders . 228
Delivery of cell therapy for pumonary disorders .. 228
Intratracheal injection of cells for pulmonary hypoplasia 228
Role of stem cells in pulmonary disorders . 229
Lung tissue regeneration from stem cells 229
Role of stem cells in construction of the Cyberlung .. 229
Respiratory epithelial cells derived from UCB stem cells . 230
Respiratory epithelial cells derived from hESCs . 230
Lung tissue engineering with adipose stromal cells .. 231
Cell-based tissue-engineering of airway .. 231
Pulmonary disorders that are treatable by stem cells . 231
Acute lung injury and ARDS treated with MSCs . 232
Bronchopulmonary dysplasia treated with MSCs.. 233
Cystic fibrosis treatment with genetically engineered MSCs .. 233
Pulmonary arterial hypertension treatment with EPCs . 233
Cell therapy for disorders of bones and joints .. 234
Repair of fractures and bone defects .. 234
Adult stem cells for bone grafting .. 235
Cell therapy for osteonecrosis . 235
ESCs for bone repair . 236
Intrauterine use of MSCs for osteogenesis imperfecta . 236
In vivo bone engineering as an alternative to cell transplantation 236
MSCs for repair of bone defects . 236
MSCs for repair of bone fractures .. 239
Osteocel 240
Stem cells for repairing skull defects 240
Stem cell-based bone tissue engineering 240
Osteoarthritis and other injuries to the joints 241
Mosaicplasty . 242
Autologous cultured chondrocytes . 242
Autologous intervertebral disc chondrocyte transplantation .. 243
Cartilage repair by genetically modified fibroblasts expressing TGF-?. 244
Generation of cartilage from stem cells 244
Role of cell therapy in repair of knee cartilage injuries .. 246
Role of cells in the repair of anterior cruciate ligament injury 247
Autologous tenocyte implantation in rotator cuff injury repair . 248
Platelet injection for tennis elbow . 248
Cell therapy of rheumatoid arthritis . 249
Cell therapy for diseases of the eye 249
Cell therapy for corneal repair .. 249 - 10 -
Stem cell therapy for limbal stem cell deficiency . 251
Role of stem cells in fibrosis following eye injury . 251
Cell therapy for regeneration . 252
Stem cells for regeneration 252
Stem cells for regenerating organs .. 252
Umbilical cord blood for regeneration . 253
Promotion of regeneration by Wnt/beta-catenin signaling 254
Role of stem cells in regeneration of esophageal epithelium 254
Cell therapy for regeneration of muscle wasting .. 254
MSCs for regeneration of ovaries following radiotherapy damage .. 255
Wound healing: skin and soft tissue repair . 255
Cells to form skin substitutes for healing ulcers .. 256
CellSpray for wound repair . 256
Cell therapy for burns .. 257
Closure of incisions with laser guns and cells 258
Follicular stem cells for skin and wound repair . 258
Reprogramming autologous stem cells for wound regeneration .. 259
Genetically engineered cells for wound repair .. 259
Regeneration of skin by adipose-derived stem cells 259
Repair of aging skin by injecting autologous fibroblasts 259
Role of cells in tissue engineering and reconstructive surgery . 260
Stem cells for tissue repair . 260
Scaffolds for tissue engineering 260
Improving vascularization of engineered tissues . 261
Enhancing vascularization by combining cell and gene therapy .. 261
Choosing cells for tissue engineering .. 261
ESCs vs adult SCs for tissue engineering 262
Use of adult MSCs for tissue engineering 262
Nanobiotechnology applied to cells for tissue engineering 263
Stem cells for tissue engineering of various organs 264
Engineering of healthy living teeth from stem cells .. 264
Adipose tissue-derived stem cells for breast reconstruction .. 265
Improving tissue engineering of bone by MSCs . 265
Intra-uterine repair of congenital defects using amniotic fluid MSCs .. 265
Cell-based tissue engineering in genitourinary system .. 266
Urinary incontinence.. 266
Tissue engineering of urinary bladder .. 267
Label retaining urothelial cells for bladder repair .. 268
Repair of the pelvic floor with stem cells from the uterus .. 268
Reconstruction of vagina from stem cells 268
Facial skin regeneration by stem cells as an alternative to face transplant .. 268
Cell therapy for rejuvenation . 269
Cell therapy for performance enhancement in sports 269
Application of stem cells in veterinary medicine .. 269
Use of stem cells to repair tendon injuries . 269
Stem cells for spinal cord injury in dogs . 270
5. Cell Therapy for Cardiovascular Disorders 271
Introduction to cardiovascular disorders . 271
Limitations of current therapies for myocardial ischemic disease 271
Types of cell therapy for cardiovascular disorders .. 271
Cell-mediated immune modulation for chronic heart disease .. 272
Human cardiovascular progenitor cells 273
Inducing the proliferation of cardiomyocytes 273
Role of the SDF-1-CXCR4 axis in stem cell therapies for myocardial ischemia 274
Role of splenic myocytes in repair of the injured heart .. 274
Small molecules to enhance myocardial repair by stem cells .. 274
Cell therapy for atherosclerotic coronary artery disease.. 275
MyoCell™ (Bioheart). 275
Cardiac stem cells . 276
Cardiomyocytes derived from epicardium .. 276
Methods of delivery of cells to the heart .. 277
Cellular cardiomyoplasty . 277
IGF-1 delivery by nanofibers to improve cell therapy for MI . 277
Non-invasive delivery of cells to the heart by Morph®guide catheter 278
Cell therapy for cardiac revascularization 278
Transplantation of cardiac progenitor cells for revascularization of myocardium 278
Stem cells to prevent restenosis after coronary angioplasty. 278
Role of cells in cardiac tissue repair 279
Transplantation of myoblasts for myocardial infarction .. 279
Patching myocardial infarction with fibroblast culture 280 - 11 -
Cardiac repair with myoendothelial cells from skeletal muscle 280
Myocardial tissue engineering 281
Role of stem cells in repair of the heart 282
Role of stem cells in cardiac regeneration following injury 282
Cardiomyocytes derived from adult skin cells .. 282
Cardiomyocytes derived from ESCs . 282
Studies to identify subsets of progenitor cells suitable for cardiac repair . 283
Technologies for preparation of stem cells for cardiovascular therapy .. 284
Pravastatin for expansion of endogenous progenitor and stem cells 284
Cytokine preconditioning of human fetal liver CD133+ SCs .. 284
Expansion of adult cardiac stem cells for transplantation 285
Role of ESCs in repair of the heart .. 285
ESC transplantation for tumor-free repair of the heart 286
Transplantation of stem cells for acute myocardial infarction .. 286
Autologous bone marrow-derived stem cell therapeutics 287
Autologous bone marrow-derived mesenchymal precursor stem cells 287
Transplantation of cord blood stem cells . 287
Transplantation of hESCs . 287
Transplantation of HSCs 288
Transplantation of autologous angiogenic cell precursors .. 289
Transplantation of adipose-derived stem cells 289
Intracoronary infusion of bone marrow-derived cells for AMI 290
Intracoronary infusion of mobilized peripheral blood stem cells 290
Transplantation of endothelial cells 291
Transplantation of cardiomyocytes differentiated from hESCs .. 291
Stem cell therapy for cardiac regeneration 291
Regeneration of the chronic myocardial infarcts by HSC therapy . 292
Human mesenchymal stem cells for cardiac regeneration .. 292
In vivo tracking of MSCs transplanted in the heart .. 293
MSCs for hibernating myocardium . 293
Simultaneous transplantation of MSCs and skeletal myoblasts . 294
Transplantation of genetically modified cells . 294
Transplantation of genetically modified MSCs .. 294
Transplantation of cells secreting vascular endothelial growth factor 294
Transplantation of genetically modified bone marrow stem cells. 295
Cell transplantation for congestive heart failure .. 295
Myoblasts for treatment of congestive heart failure 295
Injection of adult stem cells for congestive heart failure 295
AngioCell gene therapy for congestive heart failure 296
Stem cell therapy for dilated cardiac myopathy 297
Role of cell therapy in cardiac arrhythmias . 297
Atrioventricular conduction block . 298
Genetically engineered cells as biological pacemakers. 298
Ventricular tachycardia 299
Prevention of myoblast-induced arrhythmias by genetic engineering 299
ESCs for correction of congenital heart defects 300
Cardiac progenitors cells for treatment of heart disease . 300
Autologus stem cells for chronic myocardial ischemia .. 301
Role of cells in cardiovascular tissue engineering 301
Construction of blood vessels with cells . 301
Targeted delivery of endothelial progenitor cells labeled with nanoparticles 302
Fetal cardiomyocytes seeding in tissue-engineered cardiac grafts .. 302
UCB progenitor cells for engineering heart valves 302
Cell therapy for peripheral vascular disease .. 303
ALD-301 .. 303
Cell/gene therapy for PVD .. 303
Colony stimulating factors for enhancing peripheral blood stem cells 303
Intramuscular autologous bone marrow cells 304
Vascular Repair Cell . 304
Clinical trials of cell therapy in cardiovascular disease . 304
Mechanism of the benefit of cell therapy for heart disease . 307
A critical evaluation of cell therapy for heart disease 307
Publications of clinical trials of cell therapy for CVD 308
Current status of cell therapy for cardiovascular disease .. 308
Future directions for cell therapy of CVD . 309
Prospects of adult stem cell therapy for repair of heart
To order this report:
Biotechnology Industry: Cell Therapy - Technologies, Markets and Companies
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article